MX346625B - Mutantes de virus de influenza y usos para los mismos. - Google Patents

Mutantes de virus de influenza y usos para los mismos.

Info

Publication number
MX346625B
MX346625B MX2014000254A MX2014000254A MX346625B MX 346625 B MX346625 B MX 346625B MX 2014000254 A MX2014000254 A MX 2014000254A MX 2014000254 A MX2014000254 A MX 2014000254A MX 346625 B MX346625 B MX 346625B
Authority
MX
Mexico
Prior art keywords
influenza virus
compositions
uses therefor
mutant
virus mutants
Prior art date
Application number
MX2014000254A
Other languages
English (en)
Other versions
MX2014000254A (es
Inventor
Bilsel Pamuk
Hatta Yasuko
Original Assignee
Flugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47423213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX346625(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Flugen Inc filed Critical Flugen Inc
Publication of MX2014000254A publication Critical patent/MX2014000254A/es
Publication of MX346625B publication Critical patent/MX346625B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation
    • C12N2760/16262—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un virus de influenza recombinante que comprende SEQ ID NO: 1, SEQ ID NO: 2 o SEQ ID NO: 3, en donde el virus comprende un gen M mutante.
MX2014000254A 2011-06-24 2012-06-21 Mutantes de virus de influenza y usos para los mismos. MX346625B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161501034P 2011-06-24 2011-06-24
PCT/US2012/043606 WO2012177924A2 (en) 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor

Publications (2)

Publication Number Publication Date
MX2014000254A MX2014000254A (es) 2014-10-14
MX346625B true MX346625B (es) 2017-03-27

Family

ID=47423213

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2014000254A MX346625B (es) 2011-06-24 2012-06-21 Mutantes de virus de influenza y usos para los mismos.
MX2017003936A MX361139B (es) 2011-06-24 2012-06-21 Mutantes de virus de influenza y usos para los mismos.
MX2017003937A MX383065B (es) 2011-06-24 2012-06-21 Mutantes de virus de influenza y usos para los mismos.
MX2021006342A MX2021006342A (es) 2011-06-24 2014-01-07 Mutantes de virus de influenza y usos para los mismos.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2017003936A MX361139B (es) 2011-06-24 2012-06-21 Mutantes de virus de influenza y usos para los mismos.
MX2017003937A MX383065B (es) 2011-06-24 2012-06-21 Mutantes de virus de influenza y usos para los mismos.
MX2021006342A MX2021006342A (es) 2011-06-24 2014-01-07 Mutantes de virus de influenza y usos para los mismos.

Country Status (11)

Country Link
US (7) US9284533B2 (es)
EP (3) EP4023749A1 (es)
JP (7) JP6253576B2 (es)
KR (7) KR102080914B1 (es)
CN (3) CN109652430B (es)
AU (5) AU2012272837B2 (es)
CA (4) CA3103774A1 (es)
DK (2) DK3447131T3 (es)
ES (1) ES2890427T3 (es)
MX (4) MX346625B (es)
WO (1) WO2012177924A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3169427B2 (ja) 1992-04-07 2001-05-28 新日本製鐵株式会社 磁気特性の優れた二方向性珪素鋼板の製造方法
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
ES2813347T3 (es) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
JP2013541493A (ja) 2010-06-17 2013-11-14 フュジアンス バイオメディカルズ インコーポレイテッド 抗ウイルス剤として有用な化合物、組成物、及び使用の方法
MX346625B (es) * 2011-06-24 2017-03-27 Flugen Inc Mutantes de virus de influenza y usos para los mismos.
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
CN104056276B (zh) * 2013-03-20 2017-05-10 上海生物制品研究所有限责任公司 一种流感病毒减毒活疫苗及其制备方法
AU2014290203B2 (en) 2013-07-15 2020-12-24 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
WO2015142671A2 (en) * 2014-03-17 2015-09-24 Flugen, Inc. Influenza virus vectors and uses therefor
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
AU2017221444B2 (en) 2016-02-19 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Improved influenza B virus replication for vaccine development
CN118272323A (zh) * 2017-02-27 2024-07-02 复尔健有限公司 流感b病毒突变体及其用途
KR102627810B1 (ko) 2017-02-27 2024-01-22 플루젠, 인코퍼레이티드 인플루엔자에 대한 면역원성 조성물
CN107151659B (zh) * 2017-03-01 2021-04-02 苏州系统医学研究所 一种流感病毒株及其应用
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
KR102370100B1 (ko) * 2019-02-15 2022-03-07 아이디바이오 주식회사 이종 인플루엔자 a 바이러스에 대한 면역/치료반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 유전자 전달체 및 치료백신
US11214799B2 (en) 2019-03-12 2022-01-04 The University Court Of The University Of Edinburg Old College HA-specific influenza virus attenuated vaccine comprising mutations in segment 7, and uses therefor
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
WO2020247844A1 (en) * 2019-06-07 2020-12-10 Flugen, Inc. Influenza virus backbone
CN110468130B (zh) * 2019-08-09 2021-08-06 中国人民解放军军事科学院军事医学研究院 流感长链非编码RNA-lnc330及其应用
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
KR20230041775A (ko) 2020-07-21 2023-03-24 플루젠, 인코퍼레이티드 인플루엔자 바이러스 백본
JP2023534840A (ja) * 2020-07-21 2023-08-14 フルゲン， インコーポレイテッド Ｍ２／ｂｍ２欠失インフルエンザベクターを使用したワクチン
CN114438043B (zh) * 2022-01-27 2023-12-15 浙江迪福润丝生物科技有限公司 一种区分感染和免疫的致弱流感病毒疫苗株及疫苗
CN114381439B (zh) * 2022-01-27 2023-12-15 浙江迪福润丝生物科技有限公司 一种同义突变结合删除突变的流感病毒的致弱方法及致弱流感病毒株和应用
CN114410681B (zh) * 2022-01-27 2024-02-13 浙江迪福润丝生物科技有限公司 一种基于m基因核苷酸片段删除的流感病毒的致弱方法以及致弱流感病毒株和应用
CN114381440B (zh) * 2022-01-27 2023-12-15 浙江迪福润丝生物科技有限公司 一组基于同义突变和/或缺失突变的a型流感病毒致弱毒株及其制备方法和应用
CN114381438B (zh) * 2022-01-27 2024-02-02 浙江迪福润丝生物科技有限公司 一种流感病毒的致弱方法及流感致弱病毒株和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6253576U (es) 1985-09-21 1987-04-02
JPH05515Y2 (es) 1987-12-16 1993-01-08
WO1998028479A1 (en) * 1996-12-20 1998-07-02 The Procter & Gamble Company A dry laid structure comprising particulate material
GB9815040D0 (en) * 1998-07-10 1998-09-09 Medical Res Council Conditional mutant
EP1276852B1 (en) 2000-04-14 2010-11-17 Wisconsin Alumni Research Foundation Viruses comprising mutated ion channel protein
EP1364006A2 (en) 2001-02-23 2003-11-26 Wisconsin Alumni Research Foundation Methods to identify mutant cells with altered sialic acid
MXPA05011250A (es) * 2003-04-23 2006-03-30 Wisconsin Alumni Res Found Virus recombinantes de la influenza que mantienen una mutacion en un gen de proteina transmembranal.
AU2004249133B2 (en) * 2003-05-28 2009-05-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
JP2007503268A (ja) * 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾化合物の送達
CN1810961B (zh) 2006-02-22 2010-05-12 中国人民解放军军事医学科学院微生物流行病研究所 一种重组流感病毒及其制备方法与应用
US9474798B2 (en) * 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
CN104059143A (zh) * 2007-11-12 2014-09-24 特罗科隆科学有限公司 用于对流行性感冒进行治疗以及诊断的组合物以及方法
US8163523B2 (en) 2008-06-11 2012-04-24 Flugen, Inc. Cell-based systems for producing influenza vaccines
US20100061995A1 (en) * 2008-09-08 2010-03-11 Damian Michael Carragher Immunotherapy To Treat Or Prevent Viral Infection
CN102414313B (zh) * 2009-05-01 2014-04-02 雷德生物科技股份公司 多基因载体编码的重组病毒样颗粒
US20110172637A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including tissue support structure
US20110172639A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Device and method for delivery of microneedle to desired depth within the skin
US20110172645A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Wearable drug delivery device including integrated pumping and activation elements
US20110172638A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including multi-functional cover
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
WO2012061556A1 (en) 2010-11-03 2012-05-10 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
TW201303143A (zh) 2011-03-22 2013-01-16 Exxonmobil Upstream Res Co 低排放渦輪機系統中用於攫取二氧化碳及產生動力的系統與方法
MX346625B (es) 2011-06-24 2017-03-27 Flugen Inc Mutantes de virus de influenza y usos para los mismos.
JP6639334B2 (ja) 2016-06-20 2020-02-05 株式会社日立製作所 業務処理フロー生成システム、生成方法および装置
JP6120237B1 (ja) 2016-06-20 2017-04-26 仁博 平嶋 サービスシステム、アプリケーションプログラム及び決済方法

Also Published As

Publication number Publication date
AU2020201760B2 (en) 2023-04-20
US20200061182A1 (en) 2020-02-27
JP6870017B2 (ja) 2021-05-12
US9919042B2 (en) 2018-03-20
ES2890427T3 (es) 2022-01-19
MX383065B (es) 2025-03-13
KR20210084710A (ko) 2021-07-07
KR102275459B1 (ko) 2021-07-09
KR102080061B1 (ko) 2020-02-21
CA2875484C (en) 2019-11-05
DK3447131T3 (da) 2021-09-13
KR20200021100A (ko) 2020-02-27
MX2014000254A (es) 2014-10-14
AU2012272837A1 (en) 2014-01-16
WO2012177924A3 (en) 2013-09-06
JP2021112196A (ja) 2021-08-05
CN103781901A (zh) 2014-05-07
CN103781901B (zh) 2019-04-12
US20160228534A1 (en) 2016-08-11
US20140127249A1 (en) 2014-05-08
CA2875484A1 (en) 2012-12-27
JP2019103516A (ja) 2019-06-27
AU2018200488A1 (en) 2018-02-08
KR20220133316A (ko) 2022-10-04
AU2018200490B2 (en) 2020-03-19
JP6496000B2 (ja) 2019-04-03
CA3055006C (en) 2021-02-09
KR102080914B1 (ko) 2020-02-26
KR20240013286A (ko) 2024-01-30
AU2020201760A1 (en) 2020-03-26
AU2018200488B2 (en) 2020-03-19
CN106995802A (zh) 2017-08-01
EP3447131A1 (en) 2019-02-27
DK2723855T3 (en) 2018-10-01
AU2012272837B2 (en) 2017-11-02
JP6253576B2 (ja) 2017-12-27
JP2018046851A (ja) 2018-03-29
NZ620242A (en) 2016-02-26
AU2018200490A1 (en) 2018-02-15
CN109652430A (zh) 2019-04-19
JP7231666B2 (ja) 2023-03-01
CA3055002C (en) 2021-02-09
US11040098B2 (en) 2021-06-22
MX361139B (es) 2018-11-28
EP4023749A1 (en) 2022-07-06
US20190060441A1 (en) 2019-02-28
CN106995802B (zh) 2021-04-09
US11207399B2 (en) 2021-12-28
EP2723855B1 (en) 2018-08-08
AU2023204165A1 (en) 2023-08-03
CA3055002A1 (en) 2012-12-27
KR20180094145A (ko) 2018-08-22
KR102446975B1 (ko) 2022-09-22
AU2012272837A2 (en) 2014-01-30
US9919043B2 (en) 2018-03-20
JP2025066111A (ja) 2025-04-22
JP2018046850A (ja) 2018-03-29
WO2012177924A2 (en) 2012-12-27
JP6445662B2 (ja) 2018-12-26
KR102628482B1 (ko) 2024-01-23
US20250090649A1 (en) 2025-03-20
US9284533B2 (en) 2016-03-15
JP2023071764A (ja) 2023-05-23
CN109652430B (zh) 2023-05-16
EP2723855A2 (en) 2014-04-30
KR20140037235A (ko) 2014-03-26
EP3447131B1 (en) 2021-08-18
US11980661B2 (en) 2024-05-14
MX2021006342A (es) 2022-05-26
KR20180094147A (ko) 2018-08-22
US20160228535A1 (en) 2016-08-11
US20220409719A1 (en) 2022-12-29
JP2014526883A (ja) 2014-10-09
CA3055006A1 (en) 2012-12-27
KR102080062B1 (ko) 2020-02-21
CA3103774A1 (en) 2012-12-27
EP2723855A4 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
WO2015142671A3 (en) Influenza virus vectors and uses therefor
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
PH12013502442A1 (en) Inactivated dengue virus vaccine
EP4494650A3 (en) Vaccine compositions having improved stability and immunogenicity
MX346245B (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
WO2010019262A3 (en) Polyvalent vaccine
PH12017500727A1 (en) Modified virus-like particles of cmv
NZ603863A (en) Concentration and lyophilization of influenza vaccine antigens
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
WO2009115917A3 (en) Improvements in preparation of influenza virus vaccine antigens
MX346596B (es) Oligodesoxinucleotidos inmunoestimuladores.
PL2658570T3 (pl) Sposoby i kompozycje szczepionki przeciwko wirusowi wirusowej biegunki bydła typu 1b
EP2643014A4 (en) HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
WO2013052095A3 (en) Vaccine
WO2006063053A3 (en) Methods of producing influenza vaccine compositions
MX2024003337A (es) Composiciones inmunogenicas contra la influenza.
MX2014004537A (es) Vacunas para el virus del papiloma humano y metodos para su uso.
WO2013026452A9 (en) Method for removing immunosuppresive properties of hiv envelope glycoproteins
MX385188B (es) Vacuna de rinitis equina.
MX2012002702A (es) Vacuna de herpesvirus bovino.
PH12012500383A1 (en) Heterlogous prime-boost immunization regimen against bluetongue virus
MX2024003507A (es) Mutantes del virus de la influenza b y usos de los mismos.
MX337687B (es) Linea celular de amniocitos humanos permanente para la produccion de virus de influenza.

Legal Events

Date Code Title Description
FG Grant or registration